JP2018502168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502168A5 JP2018502168A5 JP2017556787A JP2017556787A JP2018502168A5 JP 2018502168 A5 JP2018502168 A5 JP 2018502168A5 JP 2017556787 A JP2017556787 A JP 2017556787A JP 2017556787 A JP2017556787 A JP 2017556787A JP 2018502168 A5 JP2018502168 A5 JP 2018502168A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- dose
- fingolimod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 claims 11
- 239000006186 oral dosage form Substances 0.000 claims 10
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 5
- 229960000556 fingolimod Drugs 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000020937 fasting conditions Nutrition 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105603P | 2015-01-20 | 2015-01-20 | |
| US62/105,603 | 2015-01-20 | ||
| US201562216100P | 2015-09-09 | 2015-09-09 | |
| US62/216,100 | 2015-09-09 | ||
| PCT/US2016/013938 WO2016118515A1 (en) | 2015-01-20 | 2016-01-19 | Stable solid fingolimod dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502168A JP2018502168A (ja) | 2018-01-25 |
| JP2018502168A5 true JP2018502168A5 (OSRAM) | 2019-02-28 |
Family
ID=56417652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556787A Pending JP2018502168A (ja) | 2015-01-20 | 2016-01-19 | 安定な固体フィンゴリモド剤形 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20230149302A1 (OSRAM) |
| EP (1) | EP3247341A4 (OSRAM) |
| JP (1) | JP2018502168A (OSRAM) |
| CN (1) | CN107530301A (OSRAM) |
| AU (1) | AU2016209466A1 (OSRAM) |
| CA (1) | CA2974375A1 (OSRAM) |
| TW (1) | TW201642842A (OSRAM) |
| WO (1) | WO2016118515A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020347662A1 (en) * | 2019-09-13 | 2022-03-31 | Meiji Co., Ltd. | Solid food and solid milk |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101367574B1 (ko) * | 2003-04-08 | 2014-02-25 | 미쓰비시 타나베 파마 코퍼레이션 | Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물 |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| CA2953372C (en) * | 2006-09-26 | 2020-06-23 | Novartis Ag | Pharmaceutical composition comprising an s1p receptor modulator |
| AR068986A1 (es) * | 2007-10-12 | 2009-12-23 | Novartis Ag | Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p) |
| AU2009315735B2 (en) * | 2008-11-11 | 2013-01-10 | Novartis Ag | Salts of fingolimod |
| EP2560619A2 (en) * | 2010-04-22 | 2013-02-27 | Ratiopharm GmbH | A method of preparing an oral dosage form comprising fingolimod |
| JO3177B1 (ar) * | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| EP2609912A1 (en) * | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Pharmaceutical combination of fingolimod and nabiximols |
| US20140199382A1 (en) * | 2013-01-11 | 2014-07-17 | Cadila Healthcare Limited | Stable pharmaceutical compositions of an s1p receptor agonist |
| US9925138B2 (en) * | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
-
2016
- 2016-01-19 AU AU2016209466A patent/AU2016209466A1/en not_active Abandoned
- 2016-01-19 EP EP16740597.6A patent/EP3247341A4/en not_active Withdrawn
- 2016-01-19 JP JP2017556787A patent/JP2018502168A/ja active Pending
- 2016-01-19 WO PCT/US2016/013938 patent/WO2016118515A1/en not_active Ceased
- 2016-01-19 CA CA2974375A patent/CA2974375A1/en not_active Abandoned
- 2016-01-19 CN CN201680006946.6A patent/CN107530301A/zh active Pending
- 2016-01-20 TW TW105101755A patent/TW201642842A/zh unknown
-
2022
- 2022-12-30 US US18/091,481 patent/US20230149302A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/243,735 patent/US20240050365A1/en not_active Abandoned
-
2024
- 2024-10-18 US US18/919,763 patent/US20250041213A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525648T3 (es) | Formulaciones galénicas que comprenden Aliskiren | |
| JP2011509295A5 (OSRAM) | ||
| JP2006506378A5 (OSRAM) | ||
| JP2017506624A5 (OSRAM) | ||
| JP2010502762A5 (OSRAM) | ||
| JP2017501201A5 (OSRAM) | ||
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| JP2018520189A5 (OSRAM) | ||
| JP2017510607A5 (OSRAM) | ||
| KR20190073365A (ko) | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 | |
| JP2018507243A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| JP2018502168A5 (OSRAM) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| RU2014113941A (ru) | Суспензия для перорального введения | |
| JP5848432B2 (ja) | ミルタザピンを含有する口腔内崩壊錠 | |
| JP2008533022A5 (OSRAM) | ||
| WO2013031831A1 (ja) | 関節リウマチなどの自己免疫疾患の治療の改善方法 | |
| JP2019533672A5 (OSRAM) | ||
| KR101697773B1 (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| JP2021073275A (ja) | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 | |
| CN104936585B (zh) | 包括苯肾上腺素和扑热息痛的组合药剂 | |
| FI3777842T3 (fi) | Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi |